Company retires all credit facility debt; transaction reflects concentrating its technology on improving health system performance.

公司偿还所有信贷融资债务；该交易反映出其将技术重心集中于提升医疗系统绩效。

SALT LAKE CITY

盐湖城

,

，

Aug. 6, 2026

2026年8月6日

/PRNewswire/ -- Health Catalyst, Inc. ('Health Catalyst' or the 'Company,'Nasdaq:

/PRNewswire/ -- Health Catalyst, Inc.（“Health Catalyst”或“公司”，纳斯达克股票代码：

HCAT

HCAT

), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today announced it closed the sale of Vitalware, LLC, through which the Company conducted its Vitalware business, to Med-Metrix, LLC, a technology-enabled revenue cycle management company, on July 31, 2026.

），一家旨在加速医疗系统实现可衡量改进的医疗智能公司，今日宣布已于2026年7月31日完成向Med-Metrix, LLC（一家技术赋能的收入周期管理公司）出售Vitalware, LLC（该公司通过其开展Vitalware业务）的交易。

Having used the net cash proceeds plus cash on hand to fully repay and terminate all of its obligations under its credit facility, Health Catalyst plans to focus its capital and its people on its highest-conviction technology, designed for the pressures defining the health system agenda: managing cost, advancing clinical quality, and earning consumer loyalty, all at once..

Health Catalyst 已利用净现金收益及手头现金全额偿还并终止其信贷安排下的所有义务，计划将资本和人力集中于其最具信心的技术，该技术旨在应对塑造医疗体系议程的核心压力：同时实现成本控制、临床质量提升和消费者忠诚度赢得。

The Company plans to focus its product roadmap on delivering intelligence products that combine a client's data with the Company's $2.8 billion in documented outcomes to identify what can drive improvement for that client, then help carry that change through the organization. Organizations don't change; people do, so the Company is investing deliberately in its intelligence products to bring each plan down to what an individual can do differently, which is what Health Catalyst believes makes improvement last..

公司计划将其产品路线图的重点放在交付智能产品上，这些产品将客户的数据与公司记录的28亿美元成果相结合，以识别能够推动该客户改进的因素，然后帮助在整个组织内落实这些变革。组织本身不会改变，改变的是人。因此，公司正有针对性地对其智能产品进行投资，将每项计划细化到个人可以采取的不同行动层面。Health Catalyst认为，这正是确保持续改进的关键所在。

The transaction included $147 million in total cash consideration for Health Catalyst, subject to customary adjustments. The Company used those proceeds plus cash on hand to fully repay and retire its obligations under its credit facility, which eliminates approximately $19 million in annual interest expense on a GAAP basis, based upon annualizing the first half of 2026.

该交易包括向Health Catalyst支付的总计1.47亿美元现金对价，须受惯例调整约束。公司利用所得款项及手头现金全额偿还并结清了其信贷融资项下的债务，此举基于2026年上半年的年化数据，按公认会计准则（GAAP）计算，每年可节省约1,900万美元的利息支出。

The Company believes this strengthened balance sheet will provide financial flexibility to invest decisively in its core strategy..

公司认为，这一强化的资产负债表将为其提供财务灵活性，以在其核心战略上果断投资。

'We're excited about where we are headed,' said Ben Albert, CEO of Health Catalyst. 'To us, powerful analytics are essential, and our expertise is built on 18 years of what actually works. What comes next is the part that we believe matters most: pairing that with knowing where to act, in what order, and with what impact, and the support to help make change stick.

“我们对未来的发展方向感到兴奋，”Health Catalyst 首席执行官本·阿尔伯特表示。“对我们而言，强大的分析能力至关重要，而我们的专业优势建立在18年经过实践验证的有效经验之上。接下来是我们认为最为关键的环节：将这种分析能力与明确行动方向、优先顺序及预期影响相结合，并提供支持以确保变革得以持续落实。”

That's the problem we're working to solve, and we believe we are well-positioned to solve it.'.

“这正是我们致力于解决的问题，而且我们相信我们具备解决这一问题的有利条件。”

Health Catalyst is focusing on pairing 18 years of proprietary healthcare improvement data and analytics with AI-driven products and the human expertise to put it to work. With the divestiture behind it, Health Catalyst is investing in the intelligence layer—the proprietary data, benchmarks, and expertise that the Company believes set it apart—which is at the core of the products it's developing.

Health Catalyst 正致力于将其18年积累的专有医疗改进数据和分析与人工智能驱动的产品以及运用这些数据的专业人力专长相结合。随着资产剥离事项的完成，Health Catalyst 正加大对智能层的投入——即公司认为使其脱颖而出的专有数据、基准和专业专长，这也是其正在开发的产品的核心所在。

These are designed to deepen the advantage that turns Health Catalyst's data into results. Data is the foundation. Intelligence is what the Company is building now, with its advantage of 18 years of proprietary healthcare improvement data: $2.8 billion in documented outcomes, across more than 380 client improvement case studies. .

这些举措旨在深化将 Health Catalyst 的数据转化为成果的优势。数据是基石。公司正依托其18年专有医疗改进数据的优势，着力构建智能能力：这些数据涵盖380多个客户改进案例研究，记录了价值28亿美元的成果。

About Vitalware

关于 Vitalware

Vitalware, formerly by Health Catalyst, is a suite of mid-revenue solutions that help hospitals and health systems improve coding compliance, chargemaster management, charge capture, and price transparency across the mid-revenue cycle. It combines healthcare-specific data models, applied AI, and expert support to deliver measurable financial and operational results..

Vitalware（前身为 Health Catalyst 旗下产品）是一套面向中等收入周期环节的解决方案套件，旨在帮助医院和医疗系统提升编码合规性、收费主文件管理、费用捕获以及价格透明度。该套件融合了医疗行业专属数据模型、应用型人工智能以及专家支持，以交付可衡量的财务与运营成果。

About Health Catalyst

关于 Health Catalyst

Health Catalyst, Inc. (Nasdaq:

Health Catalyst, Inc.（纳斯达克：

HCAT

HCAT

) is a healthcare intelligence company designed to accelerate measurable improvement for health systems across cost, clinical, and consumer performance. Backed by deep domain expertise, proprietary AI-driven technology, and $2.8 billion in documented outcomes, Health Catalyst helps health systems move from data to confident, measurable action..

）是一家医疗智能公司，旨在加速医疗系统在成本、临床和消费者绩效方面的可衡量改进。Health Catalyst 凭借深厚的领域专业知识、专有的 AI 驱动技术以及 28 亿美元的可验证成果，帮助医疗系统从数据走向自信且可衡量的行动。

Advisors

顾问

Raymond James served as the exclusive financial advisor, and Latham & Watkins LLP served as outside legal counsel for Health Catalyst.

雷蒙德·詹姆斯担任独家财务顾问，而拉瑟姆·沃特金斯律师事务所则担任Health Catalyst的外部法律顾问。

Forward-Looking Statements

前瞻性陈述

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements include statements regarding Health Catalyst's competitive advantages, Health Catalyst's ability to realize the expected impact and benefits from the divestiture of Vitalware (including increased financial flexibility and ability to invest in core products), Health Catalyst's ability to execute on its strategic transformation, strategic priorities (including its product roadmap), investment strategy, long-term strategy, and growth.

本公告包含经修订的《1933年证券法》第27A条、经修订的《1934年证券交易法》第21E条以及经修订的《1995年私人证券诉讼改革法案》所定义的“前瞻性陈述”。这些前瞻性陈述包括有关Health Catalyst的竞争优势、Health Catalyst实现从剥离Vitalware中预期影响和收益的能力（包括提高财务灵活性及增强对核心产品的投资能力）、Health Catalyst执行其战略转型的能力、战略优先事项（包括其产品路线图）、投资策略、长期战略以及增长等方面的陈述。

Forward-looking statements are subject to risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. Actual results may differ materially from the results predicted, and reported results should not be considered as an indication of future performance..

前瞻性陈述受风险和不确定性的影响，并基于可能不准确的假设，这些假设可能导致实际结果与前瞻性陈述中预期或暗示的结果存在重大差异。实际结果可能与预测结果存在重大差异，已报告的结果不应被视为对未来表现的指示。

Important risks and uncertainties that could cause actual results to differ materially from Health Catalyst's expectations, plans and prospects, including the benefits that will be derived from this transaction, include without limitation, (i) changes in laws and regulations applicable to Health Catalyst's business model; (ii) changes in market or industry conditions, regulatory environment, and receptivity to Health Catalyst's technology and services; (iii) results of litigation or a security incident; (iv) the loss of one or more key clients or partners, clients reducing or eliminating their spend with Health Catalyst, client churn or down-selling in connection with the migration to Ignite or otherwise; (v) fluctuations in Health Catalyst's project-based, non-recurring revenue, (vi) macroeconomic challenges (including high inflationary and/or high interest rate environments, tariffs, or market volatility and measures taken in response thereto), natural disasters or any new public health crises, and regional or global conflicts (including in the Middle East); (vii) the divestiture of Vitalware may not achieve some or all of the expected benefits and may adversely affect Health Catalyst's business; and (viii) changes to Health Catalyst's abilities to recruit and retain qualified team members.

可能导致实际结果与 Health Catalyst 的预期、计划和前景（包括本次交易将带来的收益）产生重大差异的重要风险和不确定性包括但不限于：(i) 适用于 Health Catalyst 商业模式的法律法规发生变化；(ii) 市场或行业状况、监管环境以及对 Health Catalyst 技术和服务的接受程度发生变化；(iii) 诉讼结果或安全事件；(iv) 失去一个或多个关键客户或合作伙伴，客户减少或终止与 Health Catalyst 的合作支出，因迁移至 Ignite 平台或其他原因导致的客户流失或降级销售；(v) Health Catalyst 基于项目的非经常性收入波动；(vi) 宏观经济挑战（包括高通胀和/或高利率环境、关税、市场波动及为此采取的措施）、自然灾害或任何新的公共卫生危机，以及地区或全球冲突（包括中东地区的冲突）；(vii) Vitalware 的剥离可能无法实现部分或全部预期收益，并可能对 Health Catalyst 的业务产生不利影响；以及 (viii) Health Catalyst 招聘和留住合格团队成员的能力发生变化。

For a detailed discussion of the risk factors that could affect Health Catalyst's actual results, please refer to the risk factors identified in Health Catalyst's SEC reports, including, but not limited to, the Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2026, expected to be filed with the SEC on or about August 6, 2026, and the Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 12, 2026 and further amended on April .

有关可能影响 Health Catalyst 实际业绩的风险因素的详细讨论，请参阅 Health Catalyst 向美国证券交易委员会（SEC）提交的报告中列明的风险因素，包括但不限于：预计于 2026 年 8 月 6 日左右向 SEC 提交的截至 2026 年 6 月 30 日的财政季度 10-Q 表季度报告，以及于 2026 年 3 月 12 日向 SEC 提交并于 4 月进一步修订的截至 2025 年 12 月 31 日的年度 10-K 表年度报告。

Health Catalyst Investor Relations Contact

Health Catalyst 投资者关系联系人

Stephanie St. Clair

斯蒂芬妮·圣克莱尔

Finance and Investor Relations, SVP

财务与投资者关系高级副总裁

+1 (855)-309-6800

+1 (855)-309-6800

[email protected]

[email protected]

Health Catalyst Media Contact

Health Catalyst 媒体联系人

Kay Blazar

凯·布拉扎尔

VP, PR

副总裁，公关

SVM PR & Marketing

SVM 公关与市场营销

[email protected]

[email protected]

SOURCE Health Catalyst

来源：Health Catalyst

21

二十一

%

%

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示